If the story of newly established Relypsa Inc., a company created to develop nonabsorbed polymeric drugs for renal and cardiovascular diseases, sounds more than a little familiar, that's probably because it is. (BioWorld Today)
A month after filing a new drug application for Treanda in chronic lymphocytic leukemia, Cephalon Inc. said the drug met its endpoint in a pivotal trial in indolent non-Hodgkin's lymphoma patients who are refractory to rituximab. (BioWorld Today)
No Abstract Staff WriterGalapagos NV's drug discovery programs got a major shot in the arm with a multitarget, potential multimillion-dollar rheumatoid arthritis deal with Johnson & Johnson unit Janssen Pharmaceutica NV.At its peak, the collaboration could bring Galapagos as much as €1 billion (US$1.43 billion) in up-front payments, license fees and milestones, and could involve as many as 15 to 19 targets.
